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CASE REPORT
In December 2010, a 66-year-old woman was diagnosed with an American Joint Committee on Cancer stage IIIB (T4 N1 M0) squamous carcinoma of the lung. She received three cycles of neoadjuvant treatment with cisplatin and gemcitabine. Radiological reevaluation showed thoracic disease progression and liver relapse, which was histologically confirmed in May 2011. She therefore received second-line therapy with docetaxel without benefit; despite shrinkage of the primary tumor the liver metastases progressed and new gastric and peritoneal lesions were observed in August 2011. Histology proved gastric lesions to be metastases of primitive squamous carcinoma of the lung. Malignant ascites necessitated several paracenteses. The patient was enrolled in a translational research program for the characterization of disseminated tumor cells (DTC) in solid tumors, and tumor cells obtained from the ascites were successfully cultured and passaged as previously described.
1 A third-line treatment with vinorelbine was initiated, but the patient's condition rapidly deteriorated and she died of respiratory failure several weeks later.
Genetic analysis was performed on laser-microdissected paraffin-embedded tissue of the primary tumor, of liver and gastric metastases, and on the cell line established from DTC of the ascites. Single-cell analysis of three different DTC was also performed. Mutational status of the genes BRAF (codon 600), NRAS (codons 12, 13, and 61), KRAS (codons 12, 13, and 61) was assessed both by reversetranscriptase polymerase chain reaction and melting curve analysis, as well as by direct sequencing as further control. Results are listed in Table 1 .
The cell line established from DTC of an ascites specimen was heterozygotic with respect to NRAS codon 12 with a c.35G>A (p. G12D) mutation (MT). Single-cell analysis performed on three individual DTC from the ascites-derived cell line, however, showed homozygotic c.35G>A MT in two cells and homozygotic wild-type (WT) in one cell, indicating that actually at least two different cancer clones coexisted in the cell line. Genotyping of NRAS codon 12 at the tissue level of the primary tumor showed c.35G>A MT, the liver metastasis heterozygotic with c.35G>A MT and the gastric metastasis WT. Sequencing matched with the polymerase chain reaction results. NRAS mutational status corresponded to distinctive histological characteristics (Fig. 1) .
Discordant genetic patterns between different compartments have been reported in several tumor entities also by our own group. 2 However, in this case, because it is unlikely that a WT allele suddenly reappeared during the metastatic process, we must postulate heterogeneity of the primary tumor concerning NRAS codon 12.
3 Initial diagnosis of the T4 primary tumor was achieved by bronchoscopy, which might have missed the area enriched in WT forms. Nonetheless, two different tumor clones were clearly detected at DTC level. Peritoneal involvement was contemporary to the gastric metastasis, which on the contrary was WT and succeeded the liver metastasis, which showed heterogeneity with regard to NRAS codon 12. Histology seemed to exclude a mixture of primaries. On the basis of these observations, we have to assume that the two different clones evolved in parallel without positive selection of one clone over the other because they appeared within the same metastatic foci. The most likely explanation of our results is that two genetically distinct subclones of the primary seeded metastases with similar homing patterns. Intratumoral metastatic heterogeneity as evolution of the metastatic clone is an accepted concept. Nonetheless, to the best of our knowledge, our results indicated for the first time that metastasis seeding might not be monoclonal in contrast to common beliefs and recent findings. 4, 5 Our observation may be of relevance for targeted therapies directed against single MTs. Furthermore, disseminated tumor cells in body fluids and peripheral blood may mirror the tumor composition at the tissue level. 
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